1-3 of 3
Viktor Chirikov
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy of Subcutaneous Epcoritamab Vs Tisa-Cel in R/R LBCL CAR T-Naive and CAR T-Eligible Patients: An Indirect Comparison

Gilles Salles, Christopher P. Fox, Anthony Wang, Kavita Sail, Abualbishr Alshreef, Michael Moran, Alex Mutebi, Julie Blaedel, Viktor Chirikov, Wei-Jhih Wang, Catherine Thieblemont
Journal: Blood
Blood (2023) 142 (Supplement 1): 1733.
https://doi.org/10.1182/blood-2023-180047
Published: 2023
Journal Articles

Indirect Comparisons of the Efficacy of Subcutaneous Epcoritamab Vs Chemoimmunotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma

Gilles Salles, Anthony Wang, Alex Mutebi, Abualbishr Alshreef, Kalatu R. Davies, Gijs van de Wetering, Viktor Chirikov
Journal: Blood
Blood (2022) 140 (Supplement 1): 10934–10935.
https://doi.org/10.1182/blood-2022-158028
Published: 2022
Journal Articles

Examination of Disparities in Access to Chimeric Antigen Receptor (CAR) T Cell Therapies in Medicare Patients (Pts) with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Who Had Failed at Least 2 Prior Lines of Therapy (LOT)

Ashley Saunders, Sushmitha Inguva, Scott J Keating, Viktor Chirikov
Journal: Blood
Blood (2022) 140 (Supplement 1): 10921–10923.
https://doi.org/10.1182/blood-2022-160313
Published: 2022